A Maraveyas

Summary

Affiliation: University of Hull
Country: UK

Publications

  1. ncbi Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study
    A Maraveyas
    Department of Academic Oncology and University of Hull, Saltshouse Road, Hull HU8 9HE, UK
    Br J Cancer 92:815-9. 2005
  2. ncbi Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?
    A Maraveyas
    Queen s Centre for Oncology and Hematology, Hull and York Medical School, Department of Academic Oncology, Castle Hill Hospital, Castle Road, Hull HU16 5JQ, UK
    Br J Cancer 100:1837-41. 2009
  3. ncbi Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy
    D J Manton
    The Postgraduate Medical Institute of the University of Hull, Division of Cancer, East Yorkshire, HU6 7RX, UK
    Br J Cancer 94:427-35. 2006
  4. ncbi Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE)
    H L McCabe
    Academic Department of Oncology, Princess Royal Hospital, Saltshouse Road, Hull HU8 9HE, East Yorkshire, U.K
    Anticancer Res 23:5209-12. 2003
  5. ncbi Surgical resection with and without chemotherapy in oesophageal cancer
    A Maraveyas
    Lancet 360:1174-5; author reply 1175. 2002
  6. ncbi 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study
    A Michael
    Oncology Department, St George s Hospital, St James Wing, Blackshow Road, London SW17 0QT, UK
    Clin Oncol (R Coll Radiol) 19:150-3. 2007

Collaborators

  • D J Manton
  • A Michael
  • H L McCabe
  • M Hill
  • A Dalgleish
  • F Lofts

Detail Information

Publications6

  1. ncbi Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study
    A Maraveyas
    Department of Academic Oncology and University of Hull, Saltshouse Road, Hull HU8 9HE, UK
    Br J Cancer 92:815-9. 2005
    ..The next dose level (75 mg m(-2)) was abandoned after grade 4 bone marrow toxicity (fatal neutropenic sepsis) was seen in one out of two patients. So that the dose of 50 mg m(-2) will be taken forward for further study...
  2. ncbi Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?
    A Maraveyas
    Queen s Centre for Oncology and Hematology, Hull and York Medical School, Department of Academic Oncology, Castle Hill Hospital, Castle Road, Hull HU16 5JQ, UK
    Br J Cancer 100:1837-41. 2009
    ..This review aims to raise awareness of this neglected area and stimulate research that may lead to improvements in patient care...
  3. ncbi Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy
    D J Manton
    The Postgraduate Medical Institute of the University of Hull, Division of Cancer, East Yorkshire, HU6 7RX, UK
    Br J Cancer 94:427-35. 2006
    ....
  4. ncbi Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE)
    H L McCabe
    Academic Department of Oncology, Princess Royal Hospital, Saltshouse Road, Hull HU8 9HE, East Yorkshire, U.K
    Anticancer Res 23:5209-12. 2003
    ..Side-effects of sedation and hypotension were mild. CONCLUSION: Levomepromazine has efficacious anti-emetic qualities in the rescue of patients with high grade DCIE needing hospital admission...
  5. ncbi Surgical resection with and without chemotherapy in oesophageal cancer
    A Maraveyas
    Lancet 360:1174-5; author reply 1175. 2002
  6. ncbi 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study
    A Michael
    Oncology Department, St George s Hospital, St James Wing, Blackshow Road, London SW17 0QT, UK
    Clin Oncol (R Coll Radiol) 19:150-3. 2007
    ..On the basis of pre-clinical evidence and some clinical data, we conducted a phase II study of 13-cis-retinoic acid (13-cis-RA) in combination with gemcitabine in patients with unresectable pancreatic carcinoma...